Not applicable (the query is a concatenation of three distinct targets, not a single entity) (Not applicable for the combined target)

The compounds “BCR-ABL,” “c-KIT,” and “PDGFRβ” represent three closely related receptor tyrosine kinases and fusion proteins that serve as pivotal signaling molecules in human cells and are frequently mutated or aberrantly activated in various cancers. - BCR-ABL is a constitutively active fusion protein tyrosine kinase produced by the Philadelphia chromosome translocation and is central to the pathogenesis of chronic myeloid leukemia (CML) and some acute lymphoblastic leukemias (ALL). It drives unchecked cell proliferation and inhibits apoptosis via multiple signaling cascades (e.g., RAS/MAPK, PI3K/AKT). - c-KIT and PDGFRβ are cell surface receptor tyrosine kinases regulating cell growth and differentiation; mutations in these genes are critical drivers of various tumors, especially gastrointestinal stromal tumors (GIST) and other malignancies. Multiple small molecule inhibitors (e.g., imatinib) have been designed to target these kinases, and resistance to these therapies (often through additional kinase mutations) remains a major clinical challenge.

Other names

Philadelphia chromosome proteinBCR-ABL fusion proteinBCR-ABL1KITCD117stem cell factor receptorPlatelet-derived growth factor receptor betaPDGFRB

Inhibition of ATP binding to the kinase domain, thus blocking downstream phosphorylation events Induction of apoptosis and cell cycle arrest in target-driven tumor cells Suppression of downstream signaling pathways (e.g., RAS/RAF/MAPK, PI3K/AKT)